Abstract
The importance of dose-intensity has been suggested in breast cancer. The aim of this study was to evaluate the feasability of a high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells. Twenty-five patients with non-metastatic breast cancer received four cycles of doxorubicin (75 mg/m2) and cyclophosphamide (3000 mg/m2) at 3 week intervals. Apheresis was performed after the first cycle and if necessary after the second cycle. Stem cells were reinfused after the third and fourth cycles. G-CSF was started on day 3 of each cycle (5 μ g/kg/day) and was stopped the day before the last apheresis or when absolute neutrophil count was above 0.5 × 109/l. Median received dose-intensity was respectively 25 mg/m2/week (range 22–26) and 1000 mg/m2/week (range 904–1065) for doxorubicin and cyclophosphamide. Grade IV thrombocytopenia occurred in 8% of cycles. Two patients needed platelets and 12 red cell transfusion. Fifteen patients were readmitted for a median duration of 4 days (range 1–7). We have established a safe, outpatient, high-dose intensity doxorubicin-cyclophosphamide regimen with supporting G-CSF and blood stem cells which can be submitted for comparison with the current standards.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Viens, P., Gravis, G., Genre, D. et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrow Transplant 20, 199–203 (1997). https://doi.org/10.1038/sj.bmt.1700870
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700870
- Springer Nature Limited
Keywords
This article is cited by
-
Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study
Bone Marrow Transplantation (2006)
-
Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens
Bone Marrow Transplantation (2002)
-
High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results
Bone Marrow Transplantation (2000)
-
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle
Bone Marrow Transplantation (2000)
-
Docetaxel effectively mobilizes peripheral blood CD34+ cells
Bone Marrow Transplantation (2000)